MAPT and Brain atrophy: AD-related imaging biomarkers mainly include MRI and Positron Emission Tomography (PET) diagnosis, which respectively reveal brain atrophy and the accumulation of amyloid, tau and other proteins in the brain (van Oostveen and de Lange, 2021).